An Open-Label, Randomized, Multicenter Phase III Study in Patients With HER2-Positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab

Trial Profile

An Open-Label, Randomized, Multicenter Phase III Study in Patients With HER2-Positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Trastuzumab (Primary) ; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Metaspher
  • Sponsors Roche
  • Most Recent Events

    • 17 Oct 2016 Planned End Date changed from 1 May 2019 to 1 Aug 2019.
    • 17 Oct 2016 Planned primary completion date changed from 1 May 2019 to 1 Aug 2019.
    • 11 Oct 2016 Results (n=113) assessing patient's preference in metastatic setting and safety presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top